DJ Roche's Benefits From Covid-19 to Continue Amid Slow Vaccine Rollout -- Market Talk

1157 GMT - Roche's sales of Covid-19 tests will continue for longer than originally envisaged and will remain high into 3Q, as it is taking longer for the vaccination rollout to be completed, Credit Suisse says. The Swiss pharma major's share in PCR testing is strong and likely to be sustained for longer, it says. Furthermore, PCR tests will continue to be necessary even among vaccinated patients, who are likely to have much lower infection levels and so necessitate a more accurate test, the bank says, adding that Covid-19 is seen remaining a market opportunity for Roche in the low-single digit billion Swiss francs. Roche trades 0.8% lower at CHF306.80. (cecilia.butini@wsj.com)

(END) Dow Jones Newswires

March 24, 2021 07:57 ET (11:57 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.